GLAPY vs SUPN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
GLAPY · GLANBIA SPONS ADR EACH REP 5 COM EUR0.06$110.93 ▲ 0.00%
SUPN · Supernus Pharmaceuticals$28.61 ▲ 0.92%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- GLAPY +31.4%
- SUPN -36.6%
Head to head
| Metric | GLAPY | SUPN |
|---|---|---|
| Price | $110.93 | $28.61 |
| Change today | ▲ 0.00% | ▲ 0.92% |
| Market cap | $5.95B | $5.94B |
| Return, 3 months | -12.7% | -36.6% |
| Return, year to date | +31.4% | -42.4% |
| Return, 1 year | +31.4% | -36.9% |
| P/E (TTM) | 22.9 | – |
| P/B | 2.8 | 5.6 |
| P/E percentile vs own 5y | – | 20th |
| Dividend yield | 2.31% | – |
| Revenue growth (YoY, latest qtr) | – | +18.0% |
| Net profit growth (YoY) | – | +146.4% |
| Gross margin | – | 87.6% |
| Operating margin | – | 3.2% |
| Net margin | – | -5.1% |
| Return on equity | – | -4.2% |
| Analyst target vs. price | – | +83.9% |
| Analyst buy share | – | 83% |
| RSI (14) | 32 | 36 |
| 30-day volatility | 35.6% | 127.6% |
| Max drawdown, 1 year | -23.8% | -53.6% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GLAPY is the largest of the group by market value.
- GLAPY has returned the most over the past year.
- GLAPY has been the calmest stock over the last 30 days.